We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$25.4B
1-Year Est. Return
38.46%
This Fund
S&P 500
This Quarter
Est. Return
-3.12%
1 Year Est. Return
+38.46%
3 Year Est. Return
+154.38%
5 Year Est. Return
+223.79%
10 Year Est. Return
+923.25%
AUM
$19.3B
AUM Growth
-$1.05B
(-5.2%)
Cap. Flow
-$77.1M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
26.03%
Holding
1,444
New
138
Increased
405
Reduced
531
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$224M |
| 2 |
Brown-Forman Class B
BF.B
|
+$140M |
| 3 |
UnitedHealth
UNH
|
+$132M |
| 4 |
Monolithic Power Systems
MPWR
|
+$108M |
| 5 |
Oracle
ORCL
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$134M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 3 |
Micron Technology
MU
|
+$122M |
| 4 |
Pfizer
PFE
|
+$120M |
| 5 |
Microsoft
MSFT
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.43% |
| 2 | Healthcare | 14.49% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Sabre
SABR
$831M
| $187K | ﹤0.01% |
+36,407
| New | +$243K |
|
1177
Arcturus Therapeutics
ARCT
$216M
| $183K | ﹤0.01% |
12,322
| – | – |
|
1178
Lifetime Brands
LCUT
$219M
| $183K | ﹤0.01% |
27,081
-1,385
| -5% | -$13.1K |
|
|
MN
1179
DELISTED
MANNING & NAPIER, INC.
MN
| $182K | ﹤0.01% |
14,796
-4,317
| -23% | -$54.4K |
|
1180
BioCryst Pharmaceuticals
BCRX
$2.71B
| $180K | ﹤0.01% |
+14,285
| New | +$184K |
|
1181
FuelCell Energy
FCEL
$1.73B
| $178K | ﹤0.01% |
1,744
| – | – |
|
1182
Latham Group
SWIM
$921M
| $178K | ﹤0.01% |
49,720
+16,120
| +48% | +$92K |
|
1183
Superior Group of Companies
SGC
$213M
| $171K | ﹤0.01% |
19,256
+2,410
| +14% | +$34.7K |
|
1184
CarGurus
CARG
$3.29B
| $168K | ﹤0.01% |
11,883
-5,231
| -31% | -$106K |
|
1185
Digital Turbine
APPS
$1.5B
| $163K | ﹤0.01% |
11,344
-2,719
| -19% | -$52K |
|
1186
Pacific Biosciences
PACB
$345M
| $160K | ﹤0.01% |
27,526
+55
| +0.2% | +$316 |
|
1187
Adaptive Biotechnologies
ADPT
$4.02B
| $157K | ﹤0.01% |
+21,987
| New | +$207K |
|
|
NGM
1188
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $156K | ﹤0.01% |
+11,919
| New | +$181K |
|
1189
American Airlines Group
AAL
$9.88B
| $155K | ﹤0.01% |
+12,875
| New | +$179K |
|
|
CANO
1190
DELISTED
Cano Health, Inc.
CANO
| $154K | ﹤0.01% |
+177
| New | +$111K |
|
1191
Anavex Life Sciences
AVXL
$316M
| $151K | ﹤0.01% |
+14,599
| New | +$154K |
|
1192
Magnite
MGNI
$3.49B
| $141K | ﹤0.01% |
21,392
+469
| +2% | +$3.77K |
|
|
SWN
1193
DELISTED
Southwestern Energy Company
SWN
| $138K | ﹤0.01% |
22,573
-19,856
| -47% | -$137K |
|
|
RTL
1194
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $128K | ﹤0.01% |
21,720
| – | – |
|
1195
AGNC Investment
AGNC
$12.9B
| $127K | ﹤0.01% |
+15,031
| New | +$176K |
|
1196
Clean Energy Fuels
CLNE
$384M
| $105K | ﹤0.01% |
+19,620
| New | +$123K |
|
1197
Empire State Realty Trust
ESRT
$817M
| $103K | ﹤0.01% |
+15,720
| New | +$117K |
|
1198
Capitol Federal Financial
CFFN
$1.1B
| $101K | ﹤0.01% |
12,185
| – | – |
|
|
SFIX
1199
Stitch Fix
SFIX
$474M
| $95K | ﹤0.01% |
24,114
+3,887
| +19% | +$22.1K |
|
1200
ADT
ADT
$5.34B
| $90K | ﹤0.01% |
12,042
+1,100
| +10% | +$8.29K |
|
Similar funds
VAI
Los Angeles Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Los Angeles Capital Management held 1,444 positions worth $19.3B, down 5.2% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Los Angeles Capital Management's Q3 2022 filing shows 138 new, 405 increased, 531 reduced and 234 closed positions. Its largest new stake was Neurocrine Biosciences: 791,966 shares worth $84.1M. The largest sale was Alphabet (Google) Class C, an estimated $134M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- Los Angeles Capital Management's largest Q3 2022 buy was Neurocrine Biosciences: 791,966 shares worth $84.1M.
- Los Angeles Capital Management added most to Broadcom in Q3 2022, an estimated $224M increase.
- Los Angeles Capital Management's biggest Q3 2022 reduction was Alphabet (Google) Class C, cutting an estimated $134M.
- Los Angeles Capital Management fully exited D.R. Horton in Q3 2022, selling an estimated $37.1M.
- Los Angeles Capital Management's ten largest holdings make up 26% of its $19.3B portfolio in Q3 2022.
- Los Angeles Capital Management opened 138 new positions and closed 234 in Q3 2022.
- Los Angeles Capital Management's portfolio value fell 5.2% quarter-over-quarter to $19.3B.
Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.